2009 Volume 219 Issue 4 Pages 289-294
Total abdominal hysterectomy (TAH) is most commonly performed for benign lesions and malignant diseases of the uterus. Postoperative immuno-suppression caused by TAH has become a serious clinical problem, due to the high incidence of infectious complications after this operation. Lornoxicam (LOR) is a member of non-steroidal anti-inflammatory drugs and a cyclooxygenase inhibitor. In this study, 45 patients undergoing TAH for uterine myoma were enrolled and given intravenous injection of normal saline (untreated patients) or LOR (8 or 16 mg) preoperatively (15 patients/group). We studied the effects of LOR on postoperative immuno-suppression by determining the serum levels of three cytokines, RANTES, monocyte chemotactic protein-1 (MCP-1), and stromal cell-derived factor 1α (SDF-1α). MCP-1 and RANTES are involved in the pathophysiology of acute and chronic inflammatory processes, and SDF-1α is considered as an inflammatory chemoattractant. Following TAH, the serum levels of RANTES were reduced in the untreated patients, but were significantly higher in the patients treated with LOR. In addition, the levels of MCP-1 and SDF-1α were significantly elevated in the untreated patients, but were significantly lower in the patients treated with LOR. Furthermore, preoperative treatment with LOR 16 mg could regulate the serum levels of these three chemokines more effectively, compared to that with LOR 8 mg. In conclusion, preoperatively intravenous injection of LOR may effectively restrain the decreased serum levels of RANTES and the increased expression of MCP-1 and SDF-1α in TAH patients. LOR may help to maintain the stability of immune function of TAH patients.
